Early investigations in unresectable mCRC, whereby combination cytotoxic chemotherapy is standard, demonstrated feasibility in serial plasma ctDNA assessments with correlations in changes in ctDNA level with tumor response (by CEA and imaging) to various systemic therapy regimens [112,113,114,115]. This evidence concerns the gene CEACAM5 and neoplasm.